Skip to main content

Covid-19 antibody startup goes public in $309M IPO

Just one year after launching with the sole mission of advancing antibodies to both treat and prevent Covid-19, Adagio Therapeutics has hit the Nasdaq, raising $309 million in an IPO.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.